AdAlta releases new data on Phase 1 trial of AD-214 in Idiopathic Pulmonary Fibrosis

Latest News

AdAlta (ASX:1AD) has released new data on the potential efficacy of AD-214 in humans with Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases.

AdAlta is a clinical-stage drug discovery company developing novel therapeutic products from its i-body platform.

The company is developing AD-214 as a treatment for fibrotic diseases such as IPF. It targets and blocks the chemokine receptor CXCR4 which is a receptor involved in several cellular processes involved in fibrosis, including the migration of immune, inflammatory and fibrotic cells to the sites of injury and disease.

CEO and managing director Dr Tim Oldham said, “This new data is critically important. We have known AD-214 is efficacious in animal models of fibrotic diseases and also that it can at least partially block its target receptor for several days and even weeks after a single IV infusion.

"What we have not known is whether we could replicate the therapeutic effect seen in animals at these levels of receptor occupancy and hence at dosing frequencies acceptable in humans.

"For the first time we have been able to show that we can maximally inhibit a key fibrotic process with as little as 60 per cent receptor occupancy and that meaningful inhibition can be achieved at much lower levels.

"This supports the hypothesis that AD-214 may be able to be dosed at a clinically convenient frequency of no more than every two weeks. This information is also extremely valuable for determining appropriate dosing for AD-214 Phase II clinical studies.

"Linking a clinically measurable parameter (receptor occupancy) with efficacy answers a question commonly asked by potential commercial partners and substantially reduces the risk of Phase II studies."